Pfizer Inc.
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Last updated:
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Status:
Grant
Type:
Utility
Filling date:
3 Feb 2015
Issue date:
25 Feb 2020